Is Moderna Stock a No-Brainer Buy After a Key FDA Win?
Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.
Overview
After a significant slump following the height of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) share prices have ripped higher over the past year, surging nearly 150%. Various factors have driven Moderna's rebound, including regulatory progress on one of its most anticipated products.
Yet even as this news, plus additional promising announcements, suggests a further recovery ahead for this pandemic-era favorite, keep in mind how much of this "comeback potential" is already priced into one of the hottest biotech stocks.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.